PCVX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
308.3M
+1.8%
302.8M
-12.5%
345.9M
+26.1%
274.3M
+13.2%
242.4M
R&D
270.3M
+0.9%
267.9M
-14.4%
312.8M
+29.2%
242.1M
+15.3%
209.9M
SG&A
37.9M
+8.7%
34.9M
+5.6%
33.1M
+2.6%
32.2M
-0.7%
32.4M
Operating Income
-308274000
-1.8%
-302777000
+12.5%
-345850000
-26.1%
-274283000
-13.2%
-242380000
EBITDA
-302496000
-0.9%
-299775000
+12.6%
-342903000
-32.7%
-258322000
-7.9%
-239316000
Net Income
-297062000
-4.5%
-284302000
+11.3%
-320622000
-30.1%
-246507000
-15.8%
-212830000
EPS (Basic)
$-1.99
-1.0%
$-1.97
+14.3%
$-2.30
-27.1%
$-1.81
-16.0%
$-1.56
EPS (Diluted)
$-1.99
-1.0%
$-1.97
+14.3%
$-2.30
-27.1%
$-1.81
-16.0%
$-1.56
Shares (Diluted)
148.9M
+3.1%
144.5M
+3.6%
139.5M
+2.3%
136.4M
+0.2%
136.2M
Vaxcyte (PCVX) — Financials